Evidence map›Paper›PMID 34517737›Full record

ReviewJournal of enzyme inhibition and medicinal chemistry2021

The possible role of methylglyoxal metabolism in cancer.

Khalid O Alfarouk, Saad S Alqahtani, Saeed Alshahrani, Jakob Morgenstern, Claudiu T Supuran, Stephan J Reshkin

Abstract readReview
In one paragraph

Review in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Dual roles of methylglyoxal in cancer.Frontiers in oncology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Khalid O AlfaroukDepartment of Evolutionary Pharmacology, and Tumor Metabolism, Hala Alfarouk Cancer Center, Khartoum, Sudan.ORCID 0000-0001-8656-6117
Saad S AlqahtaniPharmacy Practice Research Unit, Clinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan, KSA.ORCID 0000-0002-6164-9095
Saeed AlshahraniPharmacology and Toxicology Department, College of Pharmacy, Jazan University, Jazan, KSA.ORCID 0000-0002-9626-219X
Jakob MorgensternDepartment of Internal Medicine I, Endocrinology and Metabolism, Heidelberg University, Germany.ORCID 0000-0001-7227-8958
Claudiu T SupuranNeurofarba Department, Universita Degli Studi di Firenze, Florence, Italy.ORCID 0000-0003-4262-0323
Stephan J ReshkinDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID 0000-0001-9757-5908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumours reprogram their metabolism to acquire an evolutionary advantage over normal cells. However, not all such metabolic pathways support energy production. An example of these metabolic pathways is the Methylglyoxal (MG) one. This pathway helps maintain the redox state, and it might act as a phosphate sensor that monitors the intracellular phosphate levels. In this work, we discuss the biochemical step of the MG pathway and interrelate it with cancer.

Indexed as

GlyoxalHumansMolecular StructureNeoplasmsGlyoxalcancerenzymeMethylglyoxalpHredox

Identifiers

PMID34517737
PMCPMC8451662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.